Ambigrast

Ambigrast

filgrastim

Manufacturer:

Reliance

Distributor:

Ambica
Concise Prescribing Info
Contents
Filgrastim (recombinant human granulocyte colony stimulating factor, rhG-CSF)
Indications/Uses
Treatment or prevention of neutropenia in patients receiving myelosuppressive cancer chemotherapy & period reduction of neutropenia in patients undergoing bone marrow transplantation. Mobilization of peripheral blood progenitor cells for use as an alternative to bone marrow transplantation, in the management of chronic neutropenia (congenital, cyclic, or idiopathic), & persistent neutropenia in patients w/ advanced HIV infection.
Dosage/Direction for Use
Adult & childn Adjunct to antineoplastic therapy 5 mcg/kg daily starting not <24 hr after last dose of antineoplastic, may be given as single daily SC inj, as continuous IV/SC infusion or as daily IV infusion over 15-30 min. Continue until neutrophil count has stabilized w/in normal range, may take up to ≥14 days. Bone marrow transplantation Initially 10 mcg/kg daily, adjusted according to response, may be given by IV infusion over 30 min or 4 hr, or by continuous IV/SC infusion over 24 hr. Mobilization of peripheral blood progenitor cells 10 mcg/kg daily may be given as single daily SC inj or by continuous infusion for 4-7 days until leukapheresis. Dose is halved to 5 mcg/kg daily by SC inj if given after myelosuppressive chemotherapy. Patients w/ congenital neutropenia Initially 12 mcg/kg daily given SC in single or divided doses & adjusted according to response. Patients w/ idiopathic or cyclic neutropenia Initially 5 mcg/kg daily given SC in single or divided doses & adjusted according to response. Patients w/ HIV infection & persistent neutropenia Initially 1 mcg/kg daily by SC inj, may be titrated up to max of 4 mcg/kg daily until a normal neutrophil count is achieved, then adjusted for maintenance according to response. Maintenance dose: 300 mcg daily on 1-7 days a wk.
Contraindications
Special Precautions
Avoid simultaneous use w/ chemotherapy & radiation therapy, & in patients receiving cytotoxic drugs, for 24 hr prior to & 24 hr after chemotherapy. May act as a growth factor for any tumor type. Monitor patients who have history of gout or malignancies regularly. Pregnancy & lactation. Not to be used in childn or adolescents weighing <45 kg. Neonates & autoimmune neutropenia of infancy.
Adverse Reactions
Mild to moderate (occasionally severe) medullary bone pain. Pyrexia, vomiting, diarrhea, asthenia, generalized pain, cough, abdominal pain, anemia, pain in extremity, nausea, anorexia, hypoaesthesia, paraesthesia, mucosal inflammation & dysuria.
Drug Interactions
May potentiate the release of neutrophils w/ lithium.
MIMS Class
Haematopoietic Agents / Supportive Care Therapy
ATC Classification
L03AA02 - filgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Presentation/Packing
Form
Ambigrast soln for inj 300 mcg/0.5 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in